Bei Akademie registrieren
UCB, BE0003739530

UCB stock trades pre-market at EUR 204.85 ahead of the Xetra open

Published on 10/20/2026 at 07:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
UCB develops treatments for neurological and immunological diseases. At Lang & Schwarz the stock trades pre-market at EUR 204.85 on October 20, 2026.

Business model and workforce

  • UCB develops treatments for neurological and immunological diseases.
  • UCB's finance profile lists 9,000 full-time employees.
  • UCB stock trades pre-market at EUR 204.85 at 7:41 a.m. CEST at Lang & Schwarz on October 20, 2026.
Makroaufnahme eines dreidimensionalen Molekülmodells mit farbigen Kugeln vor unscharfem Laborhintergrund
UCB S.A. (BE0003739530) veranschaulicht durch scharfe Makroaufnahme einer dreidimensionalen Molekülstruktur im Forschungslabor, Illustration mit AI erstellt.

UCB develops treatments for neurological and immunological diseases. UCB stock trades pre-market at EUR 204.85 at 7:41 a.m. CEST at Lang & Schwarz on October 20, 2026.

Ahead of the Xetra open

The Lang & Schwarz indication is based on a bid of EUR 204.20 and an ask of EUR 205.50. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of UCB stock.

How UCB makes money

UCB earns money by developing and commercializing medicines for neurological and immunological conditions, while its portfolio includes treatments for epilepsy, psoriasis and other diseases. A finance profile lists 9,000 full-time employees. Market context: Market report Euro Stoxx 50.

More news and analysis on UCB stock

Disclaimer...
en | BE0003739530 | UCB | boerse | 70368778 | bgmi